Company intelligence / Profile preview

ProteoGenix

Schiltigheim / Strasbourg area, Grand Est, Franceproteogenix.science ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

ProteoGenix has enabled the successful development of multiple therapeutic antibodies and improved the success rate of biomolecules reaching IND application. Their innovations include advanced cell line systems like XtenCHO™ and AI-driven approaches to antibody engineering. They have helped develop three therapeutic antibodies that reached clinical stages and over thirty more in preclinical or earlier phases for their clients.

Therapeutic areas: OtherNeurology
Modalities: Monoclonal antibodies (mAbs)Polyclonal antibodiesRecombinant proteinsPeptides
Industry: Contract Research Organization

Partnerships

Pharmaceutical companies, biotech firms, CMOs/CDMOs as service customers/partners; specific names not disclosed publicly.

Beyond the preview

Go deeper on ProteoGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProteoGenix.

Explore the full profile